VA Doctor Leads National Trial on GLP-1 Drugs for Alcohol Use Disorder

October 18, 2026 - 21:18

A physician at the Philadelphia Veterans Affairs Medical Center is heading a nationwide clinical trial that will examine whether GLP-1 receptor agonists, the class of medications best known for treating diabetes and obesity, can also help patients struggling with alcohol use disorder. The study represents one of the largest efforts yet to determine whether drugs such as semaglutide could open a new front in addiction treatment.

The trial comes as researchers increasingly look beyond weight loss when studying GLP-1 medications. Early anecdotal reports and smaller studies have suggested that patients taking these drugs often drink less alcohol, sometimes without intending to cut back. Those observations have prompted scientists to test the connection more rigorously in controlled settings.

Alcohol use disorder affects millions of Americans, yet treatment options remain limited and many patients never receive medication. If the trial shows that GLP-1 drugs reduce cravings or heavy drinking, it could offer doctors a new tool that is already familiar and widely prescribed. The national scope of the study will allow researchers to gather data across diverse patient groups, including veterans, who face elevated rates of alcohol-related harm.

Researchers caution that the work is still in its early stages and that no conclusions should be drawn until results are available. Participants will be monitored for drinking patterns, cravings, and side effects over the course of the trial. The findings could shape future guidelines and spark further investigation into how these medications act on brain pathways involved in reward and addiction.